{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Adults&page=15",
    "query": {
      "condition": "Healthy Adults",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 3472,
    "total_pages": 348,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Adults&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Adults&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T09:45:24.371Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05282030",
      "title": "Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "tolebrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 22,
      "start_date": "2022-03-10",
      "completion_date": "2022-08-02",
      "has_results": false,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05282030"
    },
    {
      "nct_id": "NCT01986556",
      "title": "Lesinurad Tablet Relative Bioavailability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lesinurad 400 mg (Site 1)",
          "type": "DRUG"
        },
        {
          "name": "Lesinurad 400 mg (Site 2, Lot A)",
          "type": "DRUG"
        },
        {
          "name": "Lesinurad 400 mg (Site 2, Lot B)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2013-11",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01986556"
    },
    {
      "nct_id": "NCT03374631",
      "title": "Stimulating the Social Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "active anodal tDCS",
          "type": "DEVICE"
        },
        {
          "name": "sham tDCS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-12-01",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Richardson, Texas",
      "locations": [
        {
          "city": "Richardson",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03374631"
    },
    {
      "nct_id": "NCT01442831",
      "title": "Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Human ADME",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2010-09-09",
      "completion_date": "2010-09-22",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01442831"
    },
    {
      "nct_id": "NCT04173819",
      "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 225,
      "start_date": "2019-01-25",
      "completion_date": "2023-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173819"
    },
    {
      "nct_id": "NCT00812019",
      "title": "Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 753,
      "start_date": "2008-11",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00812019"
    },
    {
      "nct_id": "NCT00437229",
      "title": "A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nausea and Vomiting, Chemotherapy-Induced"
      ],
      "interventions": [
        {
          "name": "Casopitant (GW679769) Oral Tablets",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2007-02-19",
      "completion_date": "2007-05-15",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437229"
    },
    {
      "nct_id": "NCT02779140",
      "title": "Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Botulism"
      ],
      "interventions": [
        {
          "name": "NTM-1632",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-08-01",
      "completion_date": "2017-05-31",
      "has_results": false,
      "last_update_posted_date": "2018-10-29",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02779140"
    },
    {
      "nct_id": "NCT01673880",
      "title": "Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "E2006",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-08",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-05-22",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01673880"
    },
    {
      "nct_id": "NCT00899496",
      "title": "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "immunological diagnostic method",
          "type": "OTHER"
        },
        {
          "name": "physiologic testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 54,
      "start_date": "2005-09",
      "completion_date": "2009-10-23",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-17T09:45:24.371Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00899496"
    }
  ]
}